Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

机译：吉非替尼在表皮生长因子受体激活突变阳性非小细胞肺癌中的功效：外显子19缺失与外显子21突变有区别吗？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:This study was designed to evaluate the differential effect of epidermal growth factor receptor (EGFR) mutation status (exon 19 vs. 21) on progression-free survival (PFS) and overall survival (OS) in treatment-naïve advanced EGFR mutation-positive nonsmall cell lung cancer (NSCLC) treated with gefitinib as first-line agent.

机译：背景：本研究旨在评估表皮生长因子受体（EGFR）突变状态（外显子19与21）对未经治疗的晚期EGFR突变的无进展生存期（PFS）和总体生存期（OS）的不同影响-吉非替尼作为一线药物治疗的非小细胞肺癌阳性（NSCLC）。

著录项

期刊名称 Lung India : Official Organ of Indian Chest Society
作者
Amit Joshi; Vijay Patil; Vanita Noronha; Anuradha Chougule; Atanu Bhattacharjee; Rajiv Kumar; Supriya Goud; Sucheta More; Anant Ramaswamy; Ashay Karpe; Nikhil Pande; Arun Chandrasekharan; Alok Goel; Vikas Talreja; Abhishek Mahajan; Amit Janu; Nilendu Purandare; Kumar Prabhash;
展开▼
作者单位

展开▼
年(卷),期 2018(35),1
年度 2018
页码 27–30
总页数 8
原文格式 PDF
正文语种
中图分类
关键词
Epidermal growth factor receptor mutation exon 19 exon 21 gefitinib nonsmall cell lung cancer palliative;

机译：表皮生长因子受体突变;外显子19;外显子21;吉非替尼;非小细胞肺癌;姑息性;

相似文献

外文文献
中文文献
专利

1. Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation? [J] . Amit Joshi, Vijay Patil, Vanita Noronha, Lung India . 2018,第1期

机译：吉非替尼在表皮生长因子受体激活突变阳性非小细胞肺癌中的功效：外显子19缺失与外显子21突变有区别吗？
2. Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer [J] . Sun Hongyan, Sun Xiaoteng, Zhai Xiaoyu, Thoracic cancer. . 2016,第1期

机译：体重指数和19外显子突变是预测吉非替尼对表皮生长因子受体突变阳性的非小细胞肺癌患者疗效的因素
3. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. [J] . Sun JM, Won YW, Kim ST, Journal of Cancer Research and Clinical Oncology . 2011,第4期

机译：在韩国非小细胞肺癌患者中，根据表皮生长因子受体外显子19和外显子21突变，吉非替尼或厄洛替尼的疗效不同。
4. Steroid Receptor and Growth Factor Receptor Expression in Human Nonsmall Cell Lung Cancers Using Cells Procured by Laser-capture Microdissection [C] . Alan Kerr, II, James F. Eliason, International Symposium on Hormonal Carcinogenesis . 2008

机译：使用激光捕获微散射采购的细胞，使用激光捕获微粉的细胞的类固醇受体和生长因子受体表达
5. Design, Construction, and Verification of a LATE-PCR and Lights-On/Lights-Off Probe Assay for Mutation Detection in Exons 18-21 of the EGFR Gene: Implications for Molecular Diagnosis of Non-Small Cell Lung Carcinoma [D] . Tetrault, Shana Augustin 2012

机译：用于EGFR基因外显子18-21突变检测的LATE-PCR和开/关灯探针检测的设计，构建和验证：对非小细胞肺癌的分子诊断意义
6. U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations [O] . Sean Khozin, Gideon M. Blumenthal, Xiaoping Jiang, 2014

机译：美国食品药物管理局批准摘要：厄洛替尼用于表皮生长因子受体外显子19缺失或外显子21（L858R）替代突变的转移性非小细胞肺癌的一线治疗。
7. Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation? [O] . Amit Joshi, Vijay Patil, Vanita Noronha, 2018

机译：吉非替尼在表皮生长因子受体激活突变阳性非小细胞肺癌中的疗效：外显子19缺失与外显子21突变有何不同？

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

摘要

著录项

相似文献

相关主题

期刊订阅